31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.
48 citations
,
February 2017 in “Journal of Cosmetic Dermatology” This proposal reviews current knowledge and suggests actions for managing chemotherapy‐induced alopecia but reports no new clinical results, highlighting the need for evidence‐based guidelines.
36 citations
,
November 2016 in “European journal of dermatology/EJD. European journal of dermatology” This review examines systemic drugs that can cause changes in hair color and emphasizes the importance of reporting these adverse events, but it does not include new clinical outcomes.
8 citations
,
August 2016 in “Acta dermato-venereologica” Timolol eye-drops can cause hair loss.
8 citations
,
June 2016 in “Journal of Pharmacy Practice” This case report suggests that lisinopril may cause alopecia, which resolved after the patient switched to losartan potassium.
32 citations
,
May 2016 in “European journal of dermatology/EJD. European journal of dermatology” In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.
31 citations
,
January 2016 in “Drugs - Real World Outcomes” This review discusses the potential link between direct oral anticoagulants and hair loss, suggesting DOACs may not be a suitable alternative for patients with alopecia from traditional anticoagulants; however, no clinical results are reported.
5 citations
,
June 2015 in “Journal of dermatology” This letter to the editor describes a case of anagen effluvium due to thallium poisoning from Chinese herbal medicine and rodenticide but reports no new research findings.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.
2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
192 citations
,
January 2015 in “Journal of the American Academy of Dermatology” This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.
5 citations
,
January 2015 in “Current problems in dermatology” This article reviews the diagnostic process for hair problems, emphasizing the importance of thorough patient evaluation and communication but reports no new clinical results.
86 citations
,
August 2014 in “Journal of The American Academy of Dermatology” This article discusses the history taking and clinical examination process for diagnosing alopecia and outlines a diagnostic approach, noting that it reports no new clinical results.
110 citations
,
August 2014 in “International journal of cancer” This study found that scalp cooling significantly reduced the risk of chemotherapy-induced alopecia in breast cancer patients, while topical minoxidil and other interventions did not show significant efficacy.
17 citations
,
November 2013 in “Clinical and experimental dermatology” This case report describes repigmentation and curling of hair in a patient undergoing acitretin therapy.
218 citations
,
January 2013 in “The Lancet Oncology” This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.
9 citations
,
November 2012 in “Hepatology Research” This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.
54 citations
,
September 2012 in “Dermatologic Clinics” This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
3 citations
,
April 2012 in “Osteoporosis International” This study reports a case of a 62-year-old woman who experienced headache and hair loss after starting strontium ranelate for osteoporosis, with hair regrowth beginning two months after discontinuation of the drug.
36 citations
,
January 2012 in “Dermatology” This case report describes how discontinuing the EGFR inhibitor gefitinib led to rapid improvement of erosive scalp pustules in a woman with non-small-cell lung cancer, despite previous antibiotic and steroid treatment failures.
32 citations
,
April 2011 in “Journal of the American Academy of Dermatology” Erlotinib may cause scarring hair loss.
57 citations
,
March 2011 in “The American Journal of Dermatopathology” This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.
67 citations
,
May 2010 in “Journal of The American Academy of Dermatology” This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.
40 citations
,
May 2010 in “Australasian Journal of Dermatology” This study suggests that chronic telogen effluvium may be due to a reduction in the variance of anagen duration, resulting in recurrent hair shedding with minimal long-term hair volume loss.
88 citations
,
June 2009 in “Cleveland Clinic Journal of Medicine” This article reviews various causes of diffuse hair loss, highlighting the importance of identifying triggers through thorough examination for effective treatment and emphasizing patient education in management; it reports no new clinical findings.
64 citations
,
January 2009 in “Canadian Journal of Gastroenterology” This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.
48 citations
,
January 2008 in “European Neurology” This study demonstrated that acute thallium poisoning primarily manifests with gastrointestinal issues, polyneuropathy, and dermatological changes, and treatments like hemoperfusion and hemodialysis may improve symptoms.
40 citations
,
September 2007 in “Bone marrow transplantation” Certain chemotherapy drugs can cause permanent hair loss in stem cell transplant patients.
85 citations
,
April 2007 in “Dermatologic Clinics” This article reviews drug-induced hair changes, highlighting that while many drugs are occasionally linked to hair loss, this connection has been conclusively established for only a few, and such hair loss is typically reversible.
53 citations
,
January 2007 in “Dermatology” This study suggests that chemotherapy-induced anagen effluvium represents patterned hair loss, with most patients retaining hairlines, but patterns do not vary significantly by age, symptoms, or chemotherapy type.
97 citations
,
September 2006 in “Pharmaceutical Research” This review discusses advances in protecting against chemotherapy-induced alopecia and reports no new clinical results; calcitriol and cyclosporine A emerged as promising agents in animal models with broader efficacy across multiple chemotherapy drugs.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.
35 citations
,
January 2002 in “Dermatology” This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.
63 citations
,
March 2000 in “Annals of clinical psychiatry” This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.
37 citations
,
May 1999 in “Annals of pharmacotherapy/The annals of pharmacotherapy” This review describes psychotropic drug-related hair loss as a possible but uncommon side effect, with resolution typically achieved by discontinuing the medication, and emphasizes clinician-patient discussions for managing the condition.
119 citations
,
June 1993 in “BMJ” This article discusses the high toxicity and potential use of thallium as a poison, highlighted by two cases of intentional thallium poisoning.
34 citations
,
June 1990 in “British Journal of Dermatology” This study found that etretinate treatment led to an increase in plucked telogen hair counts, suggesting a reduction in the duration of anagen as the primary cause.
